Yan-Lan Sun1, Fen-Mei Zhou1, Hai-Rong Wang1. 1. Department of Obstetrics, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University Huai'an 223300, Jiangsu, China.
Abstract
BACKGROUND: Pomegranate ellagic polyphenols (PEP) has been used as a good medicine in many cultures throughout history. However, the mechanism of PEP regulated insulin resistance on gestational diabetes mellitus (GDM) rats is unclear. The main purpose of the present study was to explore the efficacy and mechanisms of PEP regulated in GDM rats. MATERIALS AND METHODS: Then, ELISA assay indicated that the levels of serum RBP4, Hcy, GA and FFA were lower in PEP groups than GDM groups in a dose-dependent manner. TUNEL staining showed that PEP improved the pathological changes and inhibited the cell apoptosis in the pancreatic and placenta tissues, respectively. RESULTS: We found that PEP improved the weight of pregnant rats and fetal rats and the level of blood glucose, blood biochemical index, insulin resistance in GDM rats. Results from H&E and immunohistochemical analysis found that PEP decreased the expressions of APN and Chemerin. Further, PEP decreased the levels of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and C-reactive protein (CRP), and increased the levels of 11β-hydroxy steroid dehydrogenase type 2 (11β-HSD2) and PPARα-TRB3-AKT2-p-FOXO1-GLUT2 signal related to insulin sensitivity in a dose-dependent manner. CONCLUSIONS: In conclusion, we have demonstrated that PEP may be a candidate drug for the treatment of GDM and guide the clinical therapy. AJTR
BACKGROUND:Pomegranate ellagic polyphenols (PEP) has been used as a good medicine in many cultures throughout history. However, the mechanism of PEP regulated insulin resistance on gestational diabetes mellitus (GDM) rats is unclear. The main purpose of the present study was to explore the efficacy and mechanisms of PEP regulated in GDM rats. MATERIALS AND METHODS: Then, ELISA assay indicated that the levels of serum RBP4, Hcy, GA and FFA were lower in PEP groups than GDM groups in a dose-dependent manner. TUNEL staining showed that PEP improved the pathological changes and inhibited the cell apoptosis in the pancreatic and placenta tissues, respectively. RESULTS: We found that PEP improved the weight of pregnant rats and fetal rats and the level of blood glucose, blood biochemical index, insulin resistance in GDM rats. Results from H&E and immunohistochemical analysis found that PEP decreased the expressions of APN and Chemerin. Further, PEP decreased the levels of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and C-reactive protein (CRP), and increased the levels of 11β-hydroxy steroid dehydrogenase type 2 (11β-HSD2) and PPARα-TRB3-AKT2-p-FOXO1-GLUT2 signal related to insulin sensitivity in a dose-dependent manner. CONCLUSIONS: In conclusion, we have demonstrated that PEP may be a candidate drug for the treatment of GDM and guide the clinical therapy. AJTR
Authors: Kym J Guelfi; Ming Jing Ong; Shaofu Li; Karen E Wallman; Dorota A Doherty; Paul A Fournier; John P Newnham; Jeffrey A Keelan Journal: Metabolism Date: 2017-08-24 Impact factor: 8.694
Authors: Hyemee Kim; Nivedita Banerjee; Maritza A Sirven; Yasushi Minamoto; Melissa E Markel; Jan S Suchodolski; Stephen T Talcott; Susanne U Mertens-Talcott Journal: J Nutr Biochem Date: 2017-02-27 Impact factor: 6.048
Authors: Chun Wang; Can-Xin Xu; Stacey L Krager; Kathleen M Bottum; Duan-Fang Liao; Shelley A Tischkau Journal: Environ Health Perspect Date: 2011-08-17 Impact factor: 9.031
Authors: Dustin W Davis; Jeannette Crew; Petar Planinic; James M Alexander; Arpita Basu Journal: Int J Environ Res Public Health Date: 2020-10-16 Impact factor: 3.390
Authors: Carlos Olvera-Sandoval; Héctor Enrique Fabela-Illescas; Eduardo Fernández-Martínez; María Araceli Ortiz-Rodríguez; Raquel Cariño-Cortés; José Alberto Ariza-Ortega; Juan Carlos Hernández-González; Diana Olivo; Carmen Valadez-Vega; Helen Belefant-Miller; Gabriel Betanzos-Cabrera Journal: Antioxidants (Basel) Date: 2022-03-15